{"name":"Neurocrine Biosciences, Inc.","slug":"neurocrine","ticker":"NBIX","exchange":"NASDAQ","domain":"neurocrine.com","description":"Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to","hq":"San Diego, CA","founded":0,"employees":"2000","ceo":"Kevin Gorman","sector":"Specialty Pharma","stockPrice":131.65,"stockChange":0.75,"stockChangePercent":0.57,"marketCap":"$13.2B","metrics":{"revenue":2100000000,"revenueGrowth":28.3,"grossMargin":62.7,"rdSpend":160524000,"netIncome":478600000,"cash":1480400000,"dividendYield":0,"peRatio":28.1,"fiscalYear":"FY2017"},"revenueBreakdown":[{"name":"Ingrezza","genericName":"valbenazine","slug":"valbenazine","revenue":1900000000,"yoyGrowth":0,"percentOfTotal":90.5},{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","revenue":200000000,"yoyGrowth":0,"percentOfTotal":9.5}],"timeline":[{"date":"2020-01-01","label":"Ongentys first approved","drug":"Ongentys","drugSlug":"bia-9-1067","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Crenessity first approved","drug":"Crenessity","drugSlug":"crinecerfont","type":"approval","sentiment":"positive"},{"date":"2026-06-01","label":"Ingrezza Phase 3 readout (Dyskinesia, Cerebral Palsy)","drug":"Ingrezza","drugSlug":"valbenazine","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"elagolix patent cliff ($1.5B at risk)","drug":"elagolix","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"valbenazine patent cliff ($500M at risk)","drug":"valbenazine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":1900000000,"percentOfTotal":90.5,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ingrezza","genericName":"valbenazine","slug":"valbenazine","indication":"Tardive Dyskinesia","status":"marketed","revenue":1900000000}]},{"name":"Neuroscience","slug":"neuroscience","revenue":200000000,"percentOfTotal":9.5,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","indication":"Parkinson's disease","status":"marketed","revenue":200000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Crenessity","genericName":"CRINECERFONT","slug":"crinecerfont","indication":"classic congenital adrenal hyperplasia (CAH)","status":"marketed"}]}],"pipeline":[{"name":"Ingrezza","genericName":"valbenazine","slug":"valbenazine","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter","indications":["Tardive Dyskinesia","Chorea Associated with Huntington’s Disease"],"catalyst":""},{"name":"Ongentys","genericName":"BIA 9-1067","slug":"bia-9-1067","phase":"marketed","mechanism":"Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Crenessity","genericName":"CRINECERFONT","slug":"crinecerfont","phase":"marketed","mechanism":"Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones.","indications":["classic congenital adrenal hyperplasia (CAH)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Neurocrine Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Neurocrine Biosciences reported fourth quarter and full year 2023 financial results, with revenue of $1.3 billion and a net loss of $1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Neurocrine Biosciences and AbbVie Announce Collaboration to Develop and Commercialize Elagolix for Endometriosis","summary":"Neurocrine Biosciences and AbbVie announced a collaboration to develop and commercialize elagolix for endometriosis.","drugName":"","sentiment":"positive"},{"date":"2023-08-18","type":"regulatory","headline":"FDA Approves Valbenazine for the Treatment of Chorea in Huntington's Disease","summary":"The FDA approved valbenazine for the treatment of chorea in Huntington's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJqRnVfMVdLTFhGQV9yaEZZcmJteXZHTnMtdlhuRkNRcnJEdTZlUVdvdlZUemJNQ1M0NEM0VDRrQ0x1NXpnZjJ1M3g4VTNsZ0tKTU1wQy01SFJyYkRMOVJwNzFpdTBrQ0txcll0ZWhCZlhlQUFVTUpyODUxcFRzbG1WSVZrdFMweFJGendSTUpLMUcxTFYxMDktbWo4NDFvVlREWklOVlpHdmtkeGIxSjhwZGJDZTdiTFR5dFRJUTlKWXpQZE1rTmlkYjF2RXUtelc5aDBfdjNIRVRYVkx3OXB1emZRdUE?oc=5","date":"2026-04-06","type":"deal","source":"PR Newswire","summary":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire","headline":"Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio","sentiment":"neutral"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFBWaFJkc0tnU1NGcGZwZFQ1bl9feWljUmF0NTZVeDQ0VWI5MDh4MjAxc2V0cGk0YWpVY1pzTEI4WXdpZklfZ2NEVWZMN3pWMjZfQVQ4WTdGREVBaEk?oc=5","date":"2026-04-03","type":"earnings","source":"Intellectia AI","summary":"NBIX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI","headline":"NBIX Financials: Revenue Breakdown, Margins & Competitor Comparison","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRTFxQ1R1b0pfc2RCR1lEeUQ4LUNGbWxad2F2bHNiX3F5QWZCNWlsbVMtUUtmWUlObFJySDBJVDJIMS1PaTdIeWxGMkg2eHA3V3NURGlQUDJTcXdCbVo2bjMxQ0J1SGQzbnVsU3dHMEZiY3RMcVphVUJCT0pTZDZKeVYxajN0MjJlQmVOVkNaTUt5bWFraU52WHIyaVZHcHAxNWtWVlZONVduYWtjVklobFJZY3pfQzV3QnNHVThIUzA3U3hZcndPd1I4N2cxY1lURDNxNUgwU0lxSEhsT3RQR1Mydw?oc=5","date":"2026-03-18","type":"pipeline","source":"MSN","summary":"Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN","headline":"Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQYUNYU08wbXRveDNTMG9saDhrcUFCaURuanpSbkY1LTdqWVZZYVZBZ210ZlZ6NUVvVVRja05MMXJxclRsTFRCREpla3pmU2hyZ2FGS2tpRUV1d2FVTnJ6WkhDN1J3RmgxcGYtUXJwMWdZLVphaEx3Z0ZXTVBGN3hoTUFRQ3lSWlJ0X21JYjBUcWZJWERFNnpvdmpFN2ozbXBEZkRkUHVmeUUyMGN5N1FHMDFMVFpqNmtSLWNhUEZsdWRPOUww?oc=5","date":"2026-03-10","type":"pipeline","source":"PR Newswire","summary":"Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PR Newswire","headline":"Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOMGhMcXlCV2tSOXBhTWlPVF8wZE5FcldlZFp6Mm0tdzFtS0prVFltTHg3MDJWRC1tMmdxYXRhRGFOMXl0Z3hxcnhGN1VxLWx2MjU1dHlIeDNvcGpraFd3eW1LLXJ2SWl3aG84OFBjb0p4WnlPbXZ3Q3FRTmZDaFpuN08wM1dQRHJ2bExBTzllSDFFWTRXYWZROVNHTQ?oc=5","date":"2026-02-12","type":"earnings","source":"BioPharma Dive","summary":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive","headline":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor","sentiment":"neutral"},{"date":"2026-02-11","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQUlBoc2poZFI2SUdkY3ViVmFWYVcwY3VxTjRqZ0dZSEVoQWtSRU8tWms2OTQ2OWhPY3ZNU25iNDZPc1dHZTlJUEJXYlJ3SW9fM3l3WGxZalJUbFhmOTFrdHZGaWd0R0tMYUlFblJIcVBWZVJIR1BFNDk4WmttV3BSR1lKUnYyd0g3NDJ6TDAxWnl3MEgzdV9tZ2NTZTdRUHR5NGVnMDNLT0VLUWo4TDkwOWo1aWZEVEVkQmdQXw?oc=5","date":"2026-02-05","type":"earnings","source":"TradingView","summary":"Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQN2NoeU1fVGZKVEx3QWZucUdmTGR1cGIzY2pRc0RtMDdYamZtTFFncWlORzFjNUEzbXZTTmFQMXFhWHR2V0I2QlR2TEE4Rjk0ZjJTdXZxaU1CaTJWSU1rMWx5UzR1NlRXRW80SDdBWWZUZmwzT2JvNUl2UktMclNWQWtQZjNPYy1kbndjS3VBcFBBQjVfcTJZeUotYklJQ3F4YXNiT3JhTGNMLUpnYWFvN1FUcTNYUFFBd0Y3Z1BFVUZScXczRU5mbWlLNkVOQzVuejJFbXRSaDlRYXQ4c0wyMzZyUFpBRkpGM0ZfMUFZRnJMTkw4dHc?oc=5","date":"2025-12-16","type":"pipeline","source":"PR Newswire","summary":"Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire","headline":"Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQc2R1ekZrd0tQNWxwc1lPMGpKTnJJeUpiSEl4Y3h2dm9OXzZrRzFieVZ2OXRhQnRUZDNjbldicUhXVmFxVHFibFM5Zktxcm9WLV9iTnVyMWtHLUE1M3FXUDk4eHFaRUV2VGVScXlJUXN3LURGbXlrZlJ5N2VGMzJ4cDIzbzlyWFFKV2ZxdDY1QmFLVDBSVGZRWXNEcVdqYzhPT0NTdl8yM1EtMm1D?oc=5","date":"2025-11-18","type":"pipeline","source":"San Diego Business Journal","summary":"New HQ, Thriving Drugs Fueling Neurocrine Expansion - San Diego Business Journal","headline":"New HQ, Thriving Drugs Fueling Neurocrine Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNN2M1VWJHdGVQVmFOZHlCNm1sMmd0SjVkSm5RTWtPaHZxbzdoTTZsMVBJekkzTjJGZHIzN1B3OEdLQWdGSDA2aFVNb0cxZzJ4Q0hnUkMxTVdscC1hVlBoeDNQNzBYRHBqSENCWWJScV9UOXROd0h5YkJOaGozZ0RSM0JOOWQ5dVFicW92aUQ4NDlSQ2l2cjlMMy1EVjYxYjlsWFgyU2Z4OUladFFmSkFEQXItQVNDSXVVcFRjUTZ2RkVBWi1MLVptNENYZlJuNWxKcjVtNVhrVktUQmNpMlY3UVVSVXdUMXIzM2dxR2YwN1puOWJ2MXpXSlhmRy12UQ?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise - PR Newswire","headline":"Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQYmlZbUxEbnMxX0JZd2pkNkdpQ1FfQ0FyTmdNS08xYmpORTB6cE9Odmk0U3BTeGZTLVRaem1zczZlc3ZNYU4wOWR2WmFZLWRUeUJjQ1hNeTBQT1Y0YkhCckRxM05TQlZGZEFETGRzbWJqT0JvamJ1Qk01Ym0zQ09QV2hWVkZzODR0V04tbGxKSlJadXllNlFSNXktM0tBNHk3Q3lvN1h3Nk5zZlNHTnpRU2xpNHpJbDVPNkN2czFielZhQjBYVUxSRGJvUXRHWklWVlY1REVLbV8waWR2b0E?oc=5","date":"2025-02-21","type":"pipeline","source":"PR Newswire","summary":"Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program - PR Newswire","headline":"Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOWjNxOGQyUXBtMTBMN0lBcHZ3TTRqN1ZiRXA1Z3NQcWFUSXJEOUtnQXNNT0xOSEVuOWJicFkzN2ZKUUIyOGJFbmNOZC1VRUx1N2dWa2ZoVFdudDZ2Zm5nQnhaQ0U3MEhJSU5wYzNiZTJpSlpaYUZyUXhNaGNESlpGelJKVHU5ZDczLXc?oc=5","date":"2024-11-30","type":"earnings","source":"Yahoo Finance","summary":"Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now? - Yahoo Finance","headline":"Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPUm8xZkpkSlV5bjF4OWdfSDVIelA2RGZQOWgyODE0S1Q0eGZBeFNnN2xQZUgyU005aXhjcEJURzNzbzZOaXBqdklOWTE3TkQwekdYeGQ1V0FGSFVYajJ1Vl84OFN4SWQ3QUVNaVJsdkEzaldRV3dZaGdkRW1RWFZkOFlNUEhOTTF4TUJLODBlZWxhZw?oc=5","date":"2024-08-21","type":"pipeline","source":"The City University of New York","summary":"Analysts: Neurocrine Biosciences Inc (NBIX) Stock Could Go to $96 - The City University of New York","headline":"Analysts: Neurocrine Biosciences Inc (NBIX) Stock Could Go to $96","sentiment":"neutral"}],"patents":[{"drugName":"elagolix","drugSlug":"elagolix","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"valbenazine","drugSlug":"valbenazine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":500000000}],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AbbVie","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Neurological Disorders","Endocrine Disorders"],"financials":{"source":"sec_edgar","revenue":161626000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":161626000,"period":"2017-12-31"},{"value":94517000,"period":"2017-12-31"},{"value":60774000,"period":"2017-09-30"},{"value":6335000,"period":"2017-06-30"},{"value":0,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":160524000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":478600000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":4631500000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":131.65,"previousClose":130.9,"fiftyTwoWeekHigh":160.18,"fiftyTwoWeekLow":84.23,"fiftyTwoWeekRange":"84.23 - 160.18","fiftyDayAverage":131.82,"twoHundredDayAverage":137.24,"beta":0.35,"enterpriseValue":12128477184,"forwardPE":13.5,"priceToBook":4.05,"priceToSales":4.62,"enterpriseToRevenue":4.24,"enterpriseToEbitda":18.2,"pegRatio":0,"ebitda":666600000,"ebitdaMargin":23.3,"freeCashflow":397812512,"operatingCashflow":782700032,"totalDebt":471300000,"debtToEquity":14.5,"currentRatio":3.39,"returnOnAssets":9.5,"returnOnEquity":16.4,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":27,"targetMeanPrice":182.88,"targetHighPrice":250.65,"targetLowPrice":140,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":820195200,"insiderHeldPercent":1.1,"institutionHeldPercent":101.8,"sharesOutstanding":100363463,"floatShares":99073793,"sharesShort":3858266,"shortRatio":3.61,"shortPercentOfFloat":3.8,"epsTrailing":4.68,"epsForward":9.72,"revenuePerShare":28.75,"bookValue":32.5,"officers":[{"age":52,"name":"Mr. Kyle W. Gano Ph.D.","title":"CEO & Director"},{"age":45,"name":"Mr. Matthew C. Abernethy CPA","title":"Chief Financial Officer"},{"age":60,"name":"Dr. Jude  Onyia Ph.D.","title":"Chief Scientific Officer"},{"age":60,"name":"Mr. Eric S. Benevich","title":"Chief Commercial Officer"},{"age":60,"name":"Dr. Eiry Wyn Roberts M.D.","title":"Strategic Advisor"},{"age":83,"name":"Dr. Wylie W. Vale Ph.D.","title":"Co-Founder"},{"age":77,"name":"Dr. Lawrence  Steinman BA, M.D., Ph.D.","title":"Co-Founder of Neurocrine"},{"age":null,"name":"Mr. Lewis  Choi","title":"Chief Information Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.neurocrine.com/index.cfm?navid=6","website":"https://www.neurocrine.com","phone":"858 617 7600"}}